Terms: = Lymphoma AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
236 results:
1. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract] [Full Text] [Related]
2. 2021 WHO Classification of Lung Cancer: Molecular Biology Research and Radiologic-Pathologic Correlation.
Sasaki T; Kuno H; Hiyama T; Oda S; Masuoka S; Miyasaka Y; Taki T; Nagasaki Y; Ohtani-Kim SJ; Ishii G; Kaku S; Shroff GS; Kobayashi T
Radiographics; 2024 Mar; 44(3):e230136. PubMed ID: 38358935
[TBL] [Abstract] [Full Text] [Related]
3. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
4. Usefulness of an RNA extraction-free test for the multiplexed detection of
Damiola F; Alberti L; Mansuet-Lupo A; Damotte D; Hofman V; Tixier L; Penault-Llorca F; Rouquette I; Vignaud JM; Cazes A; Forest F; Begueret H; Gibault L; Badoual C; Cayre A; Taranchon-Clermont E; Duc A; Mc Leer A; Lantuejoul S
Expert Rev Mol Diagn; 2023; 23(12):1283-1291. PubMed ID: 37906110
[TBL] [Abstract] [Full Text] [Related]
5. [Receptor tyrosine kinase- fusions in paediatric spindle cell tumors].
Brenner C; Sanders C; Vokuhl C
Pathologie (Heidelb); 2023 Nov; 44(6):357-365. PubMed ID: 37819532
[TBL] [Abstract] [Full Text] [Related]
6. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
[TBL] [Abstract] [Full Text] [Related]
7. A novel TPD52L2-ROS1 gene fusion expanding the molecular alterations in inflammatory myofibroblastic tumor: case report and literature review.
Liu X; Duan Y; Wang G; Zhu P
Diagn Pathol; 2023 Sep; 18(1):105. PubMed ID: 37735390
[TBL] [Abstract] [Full Text] [Related]
8. Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies.
Aktas T; Kızmazoglu D; Aktas S; Erol A; Serinan E; Gokbayrak O; Ozdemir SM; Altun Z; Ozer E; Cecen E; Ince D; Olgun N
Front Biosci (Landmark Ed); 2023 Aug; 28(8):171. PubMed ID: 37664946
[TBL] [Abstract] [Full Text] [Related]
9. Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.
Ju G; Sun Y; Wang H; Zhang X; Mu Z; Sun D; Huang L; Lin R; Xing T; Cheng W; Liang J; Lin YS
J Clin Endocrinol Metab; 2024 Jan; 109(2):505-515. PubMed ID: 37622214
[TBL] [Abstract] [Full Text] [Related]
10. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy.
Nakano K
Jpn J Clin Oncol; 2023 Oct; 53(10):885-892. PubMed ID: 37394916
[TBL] [Abstract] [Full Text] [Related]
11. TP53 or CDKN2A/B covariation in ALK/ret/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522
[TBL] [Abstract] [Full Text] [Related]
12. Detecting ALK, ROS1, and ret fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.
Giménez-Capitán A; Sánchez-Herrero E; Robado de Lope L; Aguilar-Hernández A; Sullivan I; Calvo V; Moya-Horno I; Viteri S; Cabrera C; Aguado C; Armiger N; Valarezo J; Mayo-de-Las-Casas C; Reguart N; Rosell R; Provencio M; Romero A; Molina-Vila MA
Mol Oncol; 2023 Sep; 17(9):1884-1897. PubMed ID: 37243883
[TBL] [Abstract] [Full Text] [Related]
13. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
14. Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
Pecciarini L; Brunetto E; Grassini G; De Pascali V; Ogliari FR; Talarico A; Marra G; Magliacane G; Redegalli M; Arrigoni G; Lazzari C; Gregorc V; Bulotta A; Doglioni C; Cangi MG
Cells; 2023 Apr; 12(8):. PubMed ID: 37190044
[TBL] [Abstract] [Full Text] [Related]
15. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours.
Preobrazhenskaya EV; Suleymanova AM; Bizin IV; Zagrebin FA; Romanko AA; Saitova ES; Mulkidzhan RS; Imyanitov EN
Histopathology; 2023 Jul; 83(1):109-115. PubMed ID: 37071060
[TBL] [Abstract] [Full Text] [Related]
16. Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond.
Brea E; Rotow J
Hematol Oncol Clin North Am; 2023 Jun; 37(3):575-594. PubMed ID: 37024384
[TBL] [Abstract] [Full Text] [Related]
17. Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020.
Chi SA; Yu H; Choi YL; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Choi DH; Kim K; Jung HA; Park K
JAMA Netw Open; 2023 Mar; 6(3):e232002. PubMed ID: 36929402
[TBL] [Abstract] [Full Text] [Related]
18. Mosaic chromosomal alterations detected in men living with HIV and the relationship to non-Hodgkin lymphoma.
Lin SH; Khan SM; Zhou W; Brown DW; Vergara C; Wolinsky SM; Martínez-Maza O; Margolick JB; Martinson JJ; Hussain SK; Engels EA; Machiela MJ
AIDS; 2023 Jul; 37(8):1307-1313. PubMed ID: 36927626
[TBL] [Abstract] [Full Text] [Related]
19. Challenges and Strategies to Combat Resistance Mechanisms in Thyroid Cancer Therapeutics.
Gild ML; Bullock M; Tsang V; Clifton-Bligh RJ; Robinson BG; Wirth LJ
Thyroid; 2023 Jun; 33(6):682-690. PubMed ID: 36924302
[No Abstract] [Full Text] [Related]
20. ret aberrant cancers and ret inhibitor therapies: Current state-of-the-art and future perspectives.
Addeo A; Miranda-Morales E; den Hollander P; Friedlaender A; O Sintim H; Wu J; Mani SA; Subbiah V
Pharmacol Ther; 2023 Feb; 242():108344. PubMed ID: 36632846
[TBL] [Abstract] [Full Text] [Related]
[Next]
